Survival in Early Phase Immuno-Oncology Trials: Development and Validation of a Prognostic Index. Issue 4 (19th September 2019)

• Record Type: Journal Article
• Authors: Day, Daphne; Guo, Christina; Kanjanapan, Yada; Tran, Ben; Spreafico, Anna; Joshua, Anthony M; Wang, Lisa; Abdul Razak, Albiruni R; Leighl, Natasha B; Hansen, Aaron R; Butler, Marcus O; Siu, Lillian L; Desai, Jayesh; Bedard, Philippe L
• Is Part Of: JNCI cancer spectrum. Volume 3:Issue 4(2019)
• Publication Date: 2019-09-19
• DOI: 10.1093/jncics/pkz071
• Languages: English
• ISSNs: 2515-5091

Abstract

Abstract: Background: Immuno-oncology (IO) is rapidly evolving in early drug development. We aimed to develop and prospectively validate a prognostic index for patients treated in IO phase I trials to assist with patient selection. Methods: The development cohort included 192 advanced solid tumor patients treated in 13 IO phase I trials, targeting immune checkpoint and/or co-stimulatory molecules. A prognostic scoring system was developed from multivariate survival analysis of 10 clinical factors, and subsequently validated in two independent validation cohorts (n = 152 and n = 80). Results: In the development cohort, median age was 57.5 years (range = 20.4–84.8 years). Median progression-free survival and overall survival (OS) were 13.4 and 73.6 weeks, respectively, 90-day mortality was 16%, and overall response rate was 20%. In multivariate analysis, Eastern Cooperative Oncology Group performance status greater than or equal to 1 (hazard ratio [HR] = 3.2, 95% confidence interval [CI] = 1.8 to 5.7; P < .001), number of metastatic sites greater than 2 (HR = 2.0, 95% CI = 1.3 to 3.1; P = .003), and albumin less than the lower limit of normal (HR = 1.8, 95% CI = 1.2 to 2.7; P = .007) were independent prognostic factors; comprising the Princess Margaret Immuno-oncology Prognostic Index (PM-IPI). Patients with a score of 2–3 compared with patients with a score of 0–1 had shorter OS (HR = 3.4, 95% CI = 1.9 to 6.1; P < .001), progression-free survival (HR = 2.3, 95% CI = 1.7 to 3.2; P < .001), higher 90-day mortality (odds ratio = 8.1, 95% CI = 3.0 to 35.4; P < .001), and lower overall response rate (odds ratio = 0.4, 95% CI = 0.2 to 0.8; P = .019). The PM-IPI retained prognostic ability in both validation cohorts and performed better than previously published phase I prognostic scores for predicting OS in all three cohorts. Conclusions: The PM-IPI is a validated prognostic score for patients treated in phase I IO trials and may aid in improving patient selection.